{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:47:38Z","timestamp":1792590458761,"version":"4.5.0"},"reference-count":0,"publisher":"The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkish Journal of Medical Sciences"],"abstract":"<jats:p>Background\/aim: As SARS-CoV-2 continues to spread worldwide, this study brings to light the link that anakinra, a recombinant IL-1 receptor antagonist, has in averting grave clinical outcomes. The objectives of this meta-analysis are to investigate the effects of anakinra in interventional groups compared to control\/standard of care groups on mortality along with the provision of a prevalence estimate of the variables associated with death (C-reactive protein-CRP, ferritin, acute respiratory distress syndrome-ARDS). Materials and methods: According to the PRISMA 2020 statement guidelines, a systematic search was conducted from December 19, 2020, until December 10, 2021, with keywords including COVID-19, coronavirus, SARS-CoV-2, anakinra, mortality, across the following databases: PubMed\/MEDLINE, Scopus, Web of Science, CINAHL Plus, and Cochrane. A random-effects model was applied using RevMan 5.4 for all statistical analyses. Results: The meta-analysis pooled in 1297 participants with 565 (43.6%) patients in the anakinra group. When comparing to the control\/standard of care group, the anakinra group had a much lower risk of death (RR = 0.47. 95% CI = 0.37-0.59, Z = 6.44; P &lt; 0.001). In addition to the risk of death being reduced by around 50% in the interventional group, prognostic indicators such as CRP and ferritin were improved with fewer occurrences of severe ARDS. Conclusion: Patients with COVID-19 pneumonia may be treated with anakinra as a safe and viable treatment modality to defer adverse outcomes such as a death in the 28-day period. Despite an auspicious premise, our findings must be used with caution as adequately powered randomized, placebo-controlled trials are required to corroborate these findings.<\/jats:p>","DOI":"10.55730\/1300-0144.5345","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T09:32:52Z","timestamp":1655890372000},"page":"547-553","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy of anakinra compared to standard care of treatment for COVID-19: a metaanalysis"],"prefix":"10.55730","volume":"52","author":[{"given":"HAMNA","family":"MALIK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIRA BINT ABDUL","family":"JABBAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FARAH","family":"LATIF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AZZA","family":"SARFRAZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZOUINA","family":"SARFRAZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MUZNA","family":"SARFRAZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"34691","published-online":{"date-parts":[[2022,1,1]]},"container-title":["Turkish Journal of Medical Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:22:20Z","timestamp":1792588940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.tubitak.gov.tr\/medical\/vol52\/iss3\/3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.55730\/1300-0144.5345","relation":{},"ISSN":["1300-0144"],"issn-type":[{"value":"1300-0144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}